• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过利用 Akt 激活的代谢后果选择性地根除表现出过度活跃 Akt 的癌症。

Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation.

机构信息

Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, United States.

Research & Development Section, Jesse Brown VA Medical Center, Chicago, United States.

出版信息

Elife. 2018 Apr 24;7:e32213. doi: 10.7554/eLife.32213.

DOI:10.7554/eLife.32213
PMID:29687779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5980228/
Abstract

Akt activation in human cancers exerts chemoresistance, but pan-Akt inhibition elicits adverse consequences. We exploited the consequences of Akt-mediated mitochondrial and glucose metabolism to selectively eradicate and evade chemoresistance of prostate cancer displaying hyperactive Akt. PTEN-deficient prostate cancer cells that display hyperactivated Akt have high intracellular reactive oxygen species (ROS) levels, in part, because of Akt-dependent increase of oxidative phosphorylation. High intracellular ROS levels selectively sensitize cells displaying hyperactive Akt to ROS-induced cell death enabling a therapeutic strategy combining a ROS inducer and rapamycin in PTEN-deficient prostate tumors in mouse models. This strategy elicited tumor regression, and markedly increased survival even after the treatment was stopped. By contrast, exposure to antioxidant increased prostate tumor progression. To increase glucose metabolism, Akt activation phosphorylated HK2 and induced its expression. Indeed, HK2 deficiency in mouse models of Pten-deficient prostate cancer elicited a marked inhibition of tumor development and extended lifespan.

摘要

在人类癌症中,Akt 的激活会产生化疗耐药性,但泛 Akt 抑制会引发不良反应。我们利用 Akt 介导的线粒体和葡萄糖代谢的后果,选择性地根除和逃避 Akt 过度激活的前列腺癌的化疗耐药性。PTEN 缺陷型前列腺癌细胞中 Akt 过度激活会导致细胞内活性氧(ROS)水平升高,部分原因是 Akt 依赖性氧化磷酸化增加。高细胞内 ROS 水平选择性地使 Akt 过度激活的细胞对 ROS 诱导的细胞死亡敏感,从而使在小鼠模型中的 PTEN 缺陷型前列腺肿瘤中联合使用 ROS 诱导剂和雷帕霉素成为一种治疗策略。这种策略引发了肿瘤消退,并显著提高了即使在治疗停止后的存活率。相比之下,暴露于抗氧化剂会增加前列腺肿瘤的进展。为了增加葡萄糖代谢,Akt 的激活磷酸化 HK2 并诱导其表达。事实上,在 Pten 缺陷型前列腺癌的小鼠模型中,HK2 缺乏会显著抑制肿瘤的发展并延长寿命。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/262e0516ac69/elife-32213-resp-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3a9461ad8bfe/elife-32213-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/e6abc0b021c9/elife-32213-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/7322e647736c/elife-32213-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/dc5d3352418e/elife-32213-fig1-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/ac7369a785c9/elife-32213-fig1-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/d808721c6c65/elife-32213-fig1-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/8e06caff828e/elife-32213-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/c57b61b066b2/elife-32213-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/6606ed041296/elife-32213-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/eceac496c017/elife-32213-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/04f4b9884725/elife-32213-fig2-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/9ec972dbb3df/elife-32213-fig2-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/089a3ea90c28/elife-32213-fig2-figsupp6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/50dd5929b967/elife-32213-fig2-figsupp7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/1383c6f3f64f/elife-32213-fig2-figsupp8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/f010dceee2ae/elife-32213-fig2-figsupp9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/d06f56c339ce/elife-32213-fig2-figsupp10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/064f5369d3ac/elife-32213-fig2-figsupp11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/e678218b1293/elife-32213-fig2-figsupp12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/1a6dbfe1b6e4/elife-32213-fig2-figsupp13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3992430359bf/elife-32213-fig2-figsupp14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/6ddf65898be5/elife-32213-fig2-figsupp15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/54bbc5739c6c/elife-32213-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/11a26118a1ed/elife-32213-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/e47b224d4dd4/elife-32213-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4d907bba3211/elife-32213-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/d1c56ec11d4a/elife-32213-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/66a2e565cb23/elife-32213-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/1f86c2ae123a/elife-32213-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/ed8945d1945e/elife-32213-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/242c640ff5e8/elife-32213-fig5-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/5641be9a4a5e/elife-32213-fig5-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/0e9b55f6cb0b/elife-32213-fig5-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4fb74e49b64c/elife-32213-fig5-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4579e0662ead/elife-32213-fig5-figsupp6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/75fdb3196f66/elife-32213-fig5-figsupp7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/234fca28eee7/elife-32213-fig5-figsupp8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4a2210487eaa/elife-32213-fig5-figsupp9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/abae5a363b20/elife-32213-fig5-figsupp10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3076e7c07d2d/elife-32213-fig5-figsupp11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3be9c85afa47/elife-32213-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/8e21e3c3a52b/elife-32213-resp-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/994697ae14f9/elife-32213-resp-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/262e0516ac69/elife-32213-resp-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3a9461ad8bfe/elife-32213-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/e6abc0b021c9/elife-32213-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/7322e647736c/elife-32213-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/dc5d3352418e/elife-32213-fig1-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/ac7369a785c9/elife-32213-fig1-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/d808721c6c65/elife-32213-fig1-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/8e06caff828e/elife-32213-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/c57b61b066b2/elife-32213-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/6606ed041296/elife-32213-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/eceac496c017/elife-32213-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/04f4b9884725/elife-32213-fig2-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/9ec972dbb3df/elife-32213-fig2-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/089a3ea90c28/elife-32213-fig2-figsupp6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/50dd5929b967/elife-32213-fig2-figsupp7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/1383c6f3f64f/elife-32213-fig2-figsupp8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/f010dceee2ae/elife-32213-fig2-figsupp9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/d06f56c339ce/elife-32213-fig2-figsupp10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/064f5369d3ac/elife-32213-fig2-figsupp11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/e678218b1293/elife-32213-fig2-figsupp12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/1a6dbfe1b6e4/elife-32213-fig2-figsupp13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3992430359bf/elife-32213-fig2-figsupp14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/6ddf65898be5/elife-32213-fig2-figsupp15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/54bbc5739c6c/elife-32213-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/11a26118a1ed/elife-32213-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/e47b224d4dd4/elife-32213-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4d907bba3211/elife-32213-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/d1c56ec11d4a/elife-32213-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/66a2e565cb23/elife-32213-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/1f86c2ae123a/elife-32213-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/ed8945d1945e/elife-32213-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/242c640ff5e8/elife-32213-fig5-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/5641be9a4a5e/elife-32213-fig5-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/0e9b55f6cb0b/elife-32213-fig5-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4fb74e49b64c/elife-32213-fig5-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4579e0662ead/elife-32213-fig5-figsupp6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/75fdb3196f66/elife-32213-fig5-figsupp7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/234fca28eee7/elife-32213-fig5-figsupp8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/4a2210487eaa/elife-32213-fig5-figsupp9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/abae5a363b20/elife-32213-fig5-figsupp10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3076e7c07d2d/elife-32213-fig5-figsupp11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/3be9c85afa47/elife-32213-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/8e21e3c3a52b/elife-32213-resp-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/994697ae14f9/elife-32213-resp-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5a/5980228/262e0516ac69/elife-32213-resp-fig3.jpg

相似文献

1
Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation.通过利用 Akt 激活的代谢后果选择性地根除表现出过度活跃 Akt 的癌症。
Elife. 2018 Apr 24;7:e32213. doi: 10.7554/eLife.32213.
2
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.mTOR抑制剂可逆转前列腺癌细胞中由PTEN状态赋予的阿霉素耐药性。
Cancer Res. 2002 Nov 1;62(21):6141-5.
3
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.在Pten基因缺失的前列腺癌小鼠模型中,抗雄激素和mTOR抑制剂对肿瘤生长进展的抑制作用。
Cancer Res. 2009 Sep 15;69(18):7466-72. doi: 10.1158/0008-5472.CAN-08-4385. Epub 2009 Sep 8.
4
DUOX enzyme activity promotes AKT signalling in prostate cancer cells.双氧化酶活性促进前列腺癌细胞中的 AKT 信号通路。
Anticancer Res. 2012 Dec;32(12):5175-81.
5
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.雷帕霉素哺乳动物靶点抑制剂CCI-779单独使用或与化疗联合使用对人前列腺癌细胞及异种移植瘤的作用。
Cancer Res. 2005 Apr 1;65(7):2825-31. doi: 10.1158/0008-5472.CAN-04-3137.
6
A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.NADPH 氧化酶依赖性氧化还原信号通路介导小白菊内酯在前列腺癌细胞中选择性放射增敏作用。
Cancer Res. 2010 Apr 1;70(7):2880-90. doi: 10.1158/0008-5472.CAN-09-4572. Epub 2010 Mar 16.
7
Auriculasin-induced ROS causes prostate cancer cell death via induction of apoptosis.氧化苦参碱诱导的 ROS 通过诱导细胞凋亡导致前列腺癌细胞死亡。
Food Chem Toxicol. 2018 Jan;111:660-669. doi: 10.1016/j.fct.2017.12.007. Epub 2017 Dec 5.
8
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.雄激素依赖性和非依赖性前列腺癌细胞增殖中的信号转导通路
Endocr Relat Cancer. 2005 Mar;12(1):119-34. doi: 10.1677/erc.1.00835.
9
Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.在Pten基因敲除小鼠模型中,ATF3缺失会促进Akt激活及前列腺癌发展。
Oncogene. 2015 Sep 17;34(38):4975-84. doi: 10.1038/onc.2014.426. Epub 2014 Dec 22.
10
Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.野生型10号染色体缺失的磷酸酶和张力蛋白同源物通过调节食管鳞状细胞癌中Akt的磷酸化来提高细胞对雷帕霉素的敏感性。
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12448.

引用本文的文献

1
Mechanisms underlying prostate cancer sensitivity to reactive oxygen species: overcoming radiotherapy resistance and recent clinical advances.前列腺癌对活性氧敏感的潜在机制:克服放疗抗性及近期临床进展
Cancer Biol Med. 2025 Jul 10;22(7):747-61. doi: 10.20892/j.issn.2095-3941.2024.0584.
2
Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma.致癌性KRAS成瘾状态对肺腺癌中MTH1表达和8-氧代鸟嘌呤三磷酸酶活性有不同影响。
Redox Biol. 2025 May;82:103610. doi: 10.1016/j.redox.2025.103610. Epub 2025 Mar 23.
3
AKT kinases as therapeutic targets.

本文引用的文献

1
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.己糖激酶 2 耗竭抑制肝癌中的糖酵解并诱导氧化磷酸化,并增强二甲双胍的敏感性。
Nat Commun. 2018 Jan 31;9(1):446. doi: 10.1038/s41467-017-02733-4.
2
The molecular mechanisms of chemoresistance in cancers.癌症中化疗耐药的分子机制。
Oncotarget. 2017 Jul 6;8(35):59950-59964. doi: 10.18632/oncotarget.19048. eCollection 2017 Aug 29.
3
Akt as a target for cancer therapy: more is not always better (lessons from studies in mice).
AKT 激酶作为治疗靶点。
J Exp Clin Cancer Res. 2024 Nov 29;43(1):313. doi: 10.1186/s13046-024-03207-4.
4
CAVPENET Peptide Inhibits Prostate Cancer Cells Proliferation and Migration through PP1γ-Dependent Inhibition of AKT Signaling.CAVPENET肽通过PP1γ依赖的AKT信号抑制作用抑制前列腺癌细胞的增殖和迁移。
Pharmaceutics. 2024 Sep 12;16(9):1199. doi: 10.3390/pharmaceutics16091199.
5
The role of protein post-translational modifications in prostate cancer.蛋白质翻译后修饰在前列腺癌中的作用。
PeerJ. 2024 Aug 12;12:e17768. doi: 10.7717/peerj.17768. eCollection 2024.
6
Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer.长链非编码 RNA EPCART 通过 PI3K/AKT/mTOR 通路和 PDCD4 调控前列腺癌中的翻译。
Cancer Gene Ther. 2024 Oct;31(10):1536-1546. doi: 10.1038/s41417-024-00822-3. Epub 2024 Aug 15.
7
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer.PI3K/Akt 通路与葡萄糖代谢:癌症中的危险勾结。
Int J Biol Sci. 2024 May 27;20(8):3113-3125. doi: 10.7150/ijbs.89942. eCollection 2024.
8
The Tanshinones (Tan) Extract From Bunge Induces ROS-Dependent Apoptosis in Pancreatic Cancer via AKT Hyperactivation-Mediated FOXO3/SOD2 Signaling.丹参酮(Tan)提取物通过 AKT 过度激活介导的 FOXO3/SOD2 信号诱导胰腺癌中的 ROS 依赖性细胞凋亡。
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241258961. doi: 10.1177/15347354241258961.
9
A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.一种抑制前列腺癌细胞糖酵解的化合物可控制晚期前列腺癌的生长。
Mol Cancer Ther. 2024 Jul 2;23(7):973-994. doi: 10.1158/1535-7163.MCT-23-0540.
10
A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.一种一流的TIMM44阻断剂可抑制膀胱癌细胞生长。
Cell Death Dis. 2024 Mar 11;15(3):204. doi: 10.1038/s41419-024-06585-x.
Akt作为癌症治疗靶点:并非越多越好(来自小鼠研究的经验教训)
Br J Cancer. 2017 Jul 11;117(2):159-163. doi: 10.1038/bjc.2017.153. Epub 2017 May 30.
4
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.PI3K/AKT/mTOR信号通路改变的泛癌蛋白质基因组图谱
Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.
5
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?重编程癌症中的葡萄糖代谢:能否将其用于癌症治疗?
Nat Rev Cancer. 2016 Oct;16(10):635-49. doi: 10.1038/nrc.2016.77. Epub 2016 Sep 16.
6
Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms.Akt亚型联合缺失后自发性肝细胞癌
Cancer Cell. 2016 Apr 11;29(4):523-535. doi: 10.1016/j.ccell.2016.02.008. Epub 2016 Mar 17.
7
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors.新型2,6-二取代葡糖胺系列强效选择性己糖激酶2抑制剂的发现。
ACS Med Chem Lett. 2015 Dec 28;7(3):217-22. doi: 10.1021/acsmedchemlett.5b00214. eCollection 2016 Mar 10.
8
The PI3K/AKT Pathway as a Target for Cancer Treatment.PI3K/AKT 通路作为癌症治疗的靶点。
Annu Rev Med. 2016;67:11-28. doi: 10.1146/annurev-med-062913-051343. Epub 2015 Oct 14.
9
Oxidative stress inhibits distant metastasis by human melanoma cells.氧化应激抑制人黑色素瘤细胞的远处转移。
Nature. 2015 Nov 12;527(7577):186-91. doi: 10.1038/nature15726. Epub 2015 Oct 14.
10
Antioxidants can increase melanoma metastasis in mice.抗氧化剂可促进黑素瘤在小鼠中的转移。
Sci Transl Med. 2015 Oct 7;7(308):308re8. doi: 10.1126/scitranslmed.aad3740.